메뉴 건너뛰기




Volumn 91, Issue 3, 2011, Pages 300-308

Novel polymorphisms associated with tacrolimus trough concentrations: Results from a multicenter kidney transplant consortium

Author keywords

Cytochrome P450; Pharmacogenetics; Pharmacokinetics; Tacrolimus

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYTOCHROME P450 3A5; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TACROLIMUS;

EID: 79951511037     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318200e991     Document Type: Article
Times cited : (146)

References (70)
  • 1
    • 34548083672 scopus 로고    scopus 로고
    • Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update
    • Anglicheau D, Legendre C, Beaune P, et al. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: An update. Pharmacog-enomics 2007; 8: 835.
    • (2007) Pharmacog-enomics , vol.8 , pp. 835
    • Anglicheau, D.1    Legendre, C.2    Beaune, P.3
  • 2
    • 70349116090 scopus 로고    scopus 로고
    • Pharmacogenetics of calcineurin inhibitors in renal transplantation
    • Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 2009; 88: S62.
    • (2009) Transplantation , vol.88
    • Coto, E.1    Tavira, B.2
  • 4
    • 60849086797 scopus 로고    scopus 로고
    • Individualizationofimmunosuppres-sion: Concepts and rationale
    • Wavamunno MD, Chapman JR. Individualizationofimmunosuppres-sion: Concepts and rationale. Curr Opin Organ Transplant 2008; 13: 604.
    • (2008) Curr Opin Organ Transplant , vol.13 , pp. 604
    • Wavamunno, M.D.1    Chapman, J.R.2
  • 5
    • 33748057835 scopus 로고    scopus 로고
    • An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients
    • Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184.
    • (2006) Pharmacol Ther , vol.112 , pp. 184
    • Masuda, S.1    Inui, K.2
  • 6
    • 73349087877 scopus 로고    scopus 로고
    • Tacrolimus: Review of pharmacokinetics, pharmacodynamics, and pharmacogeneticstofacil-itate practitioners' understanding and offer strategies for educating patients and promoting adherence
    • Vicari-Christensen M, Repper S, Basile S, et al. Tacrolimus: Review of pharmacokinetics, pharmacodynamics, and pharmacogeneticstofacil-itate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009; 19: 277.
    • (2009) Prog Transplant , vol.19 , pp. 277
    • Vicari-Christensen, M.1    Repper, S.2    Basile, S.3
  • 8
    • 3242772986 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
    • Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
    • (2004) Clin Pharmacokinet , vol.43 , pp. 623
    • Staatz, C.E.1    Tett, S.E.2
  • 9
    • 38449094179 scopus 로고    scopus 로고
    • Metabolism of tacrolimus (FK506) and recent topicsinclin-ical pharmacokinetics
    • Iwasaki K. Metabolism of tacrolimus (FK506) and recent topicsinclin-ical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
    • (2007) Drug Metab Pharmacokinet , vol.22 , pp. 328
    • Iwasaki, K.1
  • 10
    • 33745487508 scopus 로고    scopus 로고
    • Active drug transport of immu-nosuppressants: New insights for pharmacokinetics and pharmacody-namics
    • Christians U, Strom T, Zhang YL, et al. Active drug transport of immu-nosuppressants: New insights for pharmacokinetics and pharmacody-namics. Ther Drug Monit 2006; 28: 39.
    • (2006) Ther Drug Monit , vol.28 , pp. 39
    • Christians, U.1    Strom, T.2    Zhang, Y.L.3
  • 11
    • 0028295725 scopus 로고
    • Metabolism of FK506, a potent immunosuppressive agent,bycytochrome P4503A enzymesinrat, dog and human liver microsomes
    • Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent,bycytochrome P4503A enzymesinrat, dog and human liver microsomes. Biochem Pharmacol 1994; 47: 727.
    • (1994) Biochem Pharmacol , vol.47 , pp. 727
    • Shiraga, T.1    Matsuda, H.2    Nagase, K.3
  • 12
    • 0027418815 scopus 로고
    • Human P-glycoprotein transports cyclosporin A and FK506
    • SaekiT,Ueda K,TanigawaraY,et al Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993. 268: 6077.
    • (1993) J Biol Chem , vol.268 , pp. 6077
    • Saeki, T.1    Ueda, K.2    Tanigawara, Y.3
  • 13
    • 0032986187 scopus 로고    scopus 로고
    • Low systemic exposure to tacrolimus correlates with acute rejection
    • Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296.
    • (1999) Transplant Proc , vol.31 , pp. 296
    • Undre, N.A.1    Van Hooff, J.2    Christiaans, M.3
  • 14
    • 68449089526 scopus 로고    scopus 로고
    • Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection
    • Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436.
    • (2009) Ther Drug Monit , vol.31 , pp. 436
    • Borobia, A.M.1    Romero, I.2    Jimenez, C.3
  • 15
    • 65349115890 scopus 로고    scopus 로고
    • Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference
    • Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009; 31: 139.
    • (2009) Ther Drug Monit , vol.31 , pp. 139
    • Wallemacq, P.1    Armstrong, V.W.2    Brunet, M.3
  • 16
    • 77249158801 scopus 로고    scopus 로고
    • Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part II
    • Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part II. Clin Pharmacokinet 2010; 49: 207.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 207
    • Staatz, C.E.1    Goodman, L.K.2    Tett, S.E.3
  • 17
    • 77249125964 scopus 로고    scopus 로고
    • Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part i
    • Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphismsonthe pharmacokinetics and pharmacody-namics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 141.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 141
    • Staatz, C.E.1    Goodman, L.K.2    Tett, S.E.3
  • 18
    • 65549149071 scopus 로고    scopus 로고
    • Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea
    • Jun KR, Lee W,Jang MS,etal. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009; 87: 1225.
    • (2009) Transplantation , vol.87 , pp. 1225
    • Jun, K.R.1    Lee, W.2    Jang, M.S.3
  • 19
    • 40549112692 scopus 로고    scopus 로고
    • CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
    • Hesselink DA, van Schaik RH, van Agteren M, et al. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008; 18: 339.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 339
    • Hesselink, D.A.1    Van Schaik, R.H.2    Van Agteren, M.3
  • 20
    • 14044278166 scopus 로고    scopus 로고
    • Tacrolimus pharmaco-genetics: The CYP3A5*1 allele predicts low dose-normalized tacroli-mus blood concentrations in whites and South Asians
    • Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmaco-genetics: The CYP3A5*1 allele predicts low dose-normalized tacroli-mus blood concentrations in whites and South Asians. Transplantation 2005; 79: 499.
    • (2005) Transplantation , vol.79 , pp. 499
    • MacPhee, I.A.1    Fredericks, S.2    Mohamed, M.3
  • 21
    • 0041831261 scopus 로고    scopus 로고
    • Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharma-cokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    • Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharma-cokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245.
    • (2003) Clin Pharmacol Ther , vol.74 , pp. 245
    • Hesselink, D.A.1    Van Schaik, R.H.2    Van Der Heiden, I.P.3
  • 22
    • 33846632909 scopus 로고    scopus 로고
    • CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients
    • Renders L, Frisman M, Ufer M, et al. CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 2007; 81: 228.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 228
    • Renders, L.1    Frisman, M.2    Ufer, M.3
  • 23
    • 33749984168 scopus 로고    scopus 로고
    • CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study
    • Haufroid V,WallemacqP,VanKerckhoveV, etal. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: Guidelines from an experimental study. Am J Transplant 2006; 6: 2706.
    • (2006) Am J Transplant , vol.6 , pp. 2706
    • Haufroid, V.1    Wallemacq, P.2    Van Kerckhove, V.3
  • 24
    • 34447549311 scopus 로고    scopus 로고
    • Tacrolimus pharma-cokinetics and pharmacogenetics: Influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms
    • Op den Buijsch RA, Christiaans MH, Stolk LM, et al. Tacrolimus pharma-cokinetics and pharmacogenetics: Influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol 2007; 21: 427.
    • (2007) Fundam Clin Pharmacol , vol.21 , pp. 427
    • Op Den Buijsch, R.A.1    Christiaans, M.H.2    Stolk, L.M.3
  • 25
    • 7044272257 scopus 로고    scopus 로고
    • Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients
    • Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 2004; 78: 1182.
    • (2004) Transplantation , vol.78 , pp. 1182
    • Tsuchiya, N.1    Satoh, S.2    Tada, H.3
  • 26
    • 2942588886 scopus 로고    scopus 로고
    • The influence of pharmacoge-netics on the time to achieve target tacrolimus concentrations after kidney transplantation
    • MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacoge-netics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
    • (2004) Am J Transplant , vol.4 , pp. 914
    • MacPhee, I.A.1    Fredericks, S.2    Tai, T.3
  • 27
    • 0242332169 scopus 로고    scopus 로고
    • Impact ofcytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients
    • Thervet E, Anglicheau D, King B, et al. Impact ofcytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003; 76: 1233.
    • (2003) Transplantation , vol.76 , pp. 1233
    • Thervet, E.1    Anglicheau, D.2    King, B.3
  • 28
    • 36148985704 scopus 로고    scopus 로고
    • CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients
    • Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term ta-crolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 711
    • Kuypers, D.R.1    De Jonge, H.2    Naesens, M.3
  • 29
    • 58149148271 scopus 로고    scopus 로고
    • Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients
    • Bandur S, Petrasek J, Hribova P, et al. Haplotypic structure of ABCB1/ MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1206.
    • (2008) Transplantation , vol.86 , pp. 1206
    • Bandur, S.1    Petrasek, J.2    Hribova, P.3
  • 30
    • 33747085521 scopus 로고    scopus 로고
    • Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients
    • Roy JN, Barama A, Poirier C, et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659.
    • (2006) Pharmacogenet Genomics , vol.16 , pp. 659
    • Roy, J.N.1    Barama, A.2    Poirier, C.3
  • 31
    • 12144286933 scopus 로고    scopus 로고
    • The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients
    • Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147.
    • (2004) Pharmacogenetics , vol.14 , pp. 147
    • Haufroid, V.1    Mourad, M.2    Van Kerckhove, V.3
  • 32
    • 65349104728 scopus 로고    scopus 로고
    • Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients
    • Press RR, Ploeger BA, den Hartigh J, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187.
    • (2009) Ther Drug Monit , vol.31 , pp. 187
    • Press, R.R.1    Ploeger, B.A.2    Den Hartigh, J.3
  • 33
    • 0038304548 scopus 로고    scopus 로고
    • Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients
    • Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 1889
    • Anglicheau, D.1    Verstuyft, C.2    Laurent-Puig, P.3
  • 34
    • 0037115210 scopus 로고    scopus 로고
    • Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement
    • Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486.
    • (2002) Transplantation , vol.74 , pp. 1486
    • MacPhee, I.A.1    Fredericks, S.2    Tai, T.3
  • 35
    • 27644467774 scopus 로고    scopus 로고
    • Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids
    • Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977.
    • (2005) Transplantation , vol.80 , pp. 977
    • Mourad, M.1    Mourad, G.2    Wallemacq, P.3
  • 36
    • 33748710224 scopus 로고    scopus 로고
    • Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements
    • Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705.
    • (2006) Transplantation , vol.82 , pp. 705
    • Fredericks, S.1    Moreton, M.2    Reboux, S.3
  • 37
    • 79951510522 scopus 로고    scopus 로고
    • Association of single nucleotide polymorphisms and acute rejection
    • Oetting W, Schladt D, Israni I, et al. Association of single nucleotide polymorphisms and acute rejection.AmJTransplant2010; 10(suppl 4); 389.
    • (2010) Am J Transplant , vol.10 , Issue.SUPPL. 4 , pp. 389
    • Oetting, W.1    Schladt, D.2    Israni, I.3
  • 38
    • 0035133672 scopus 로고    scopus 로고
    • The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
    • Mancinelli LM, FrassettoL, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24.
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 24
    • Mancinelli, L.M.1    Frassetto, L.2    Floren, L.C.3
  • 39
    • 0026662551 scopus 로고
    • Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
    • Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753.
    • (1992) Drug Metab Dispos , vol.20 , pp. 753
    • Sattler, M.1    Guengerich, F.P.2    Yun, C.H.3
  • 41
    • 33645864935 scopus 로고    scopus 로고
    • Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
    • Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836.
    • (2006) Drug Metab Dispos , vol.34 , pp. 836
    • Dai, Y.1    Hebert, M.F.2    Isoherranen, N.3
  • 42
    • 59249101691 scopus 로고    scopus 로고
    • Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans
    • Perera MA, Thirumaran RK, Cox NJ, et al. Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharma-cogenomics J 2009; 9: 49.
    • (2009) Pharma-cogenomics J , vol.9 , pp. 49
    • Perera, M.A.1    Thirumaran, R.K.2    Cox, N.J.3
  • 43
    • 77952585319 scopus 로고    scopus 로고
    • Optimization of initial tacroli-mus dose using pharmacogenetic testing
    • Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacroli-mus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010; 87: 721.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 721
    • Thervet, E.1    Loriot, M.A.2    Barbier, S.3
  • 44
    • 77949873283 scopus 로고    scopus 로고
    • Genetic and clinical predictors of warfarin dose requirements in African Americans
    • Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 459.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 459
    • Cavallari, L.H.1    Langaee, T.Y.2    Momary, K.M.3
  • 45
    • 77949874684 scopus 로고    scopus 로고
    • Apolymorphisminthe VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans
    • VooraD,Koboldt DC, King CR, etal.Apolymorphisminthe VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87: 445.
    • (2010) Clin Pharmacol Ther , vol.87 , pp. 445
    • Voora, D.1    Koboldt, D.C.2    King, C.R.3
  • 46
    • 10344264967 scopus 로고    scopus 로고
    • Pharmacokinetics of immunosup-pressants: Aperspectiveonethnic differences
    • Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosup-pressants: Aperspectiveonethnic differences.IntJClin Pharmacol Ther 2004; 42: 701.
    • (2004) Int J Clin Pharmacol Ther , vol.42 , pp. 701
    • Dirks, N.L.1    Huth, B.2    Yates, C.R.3
  • 47
    • 0032570530 scopus 로고    scopus 로고
    • Racial differences in renal transplantation after immuno-suppression with tacrolimus versus cyclosporine
    • FK506 Kidney Transplant Study Group
    • Neylan JF. Racial differences in renal transplantation after immuno-suppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
    • (1998) Transplantation , vol.65 , pp. 515
    • Neylan, J.F.1
  • 48
    • 0031859573 scopus 로고    scopus 로고
    • Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial
    • FK506 Kidney Transplant Study Group
    • Neylan JF. Effect of race and immunosuppression in renal transplantation: Three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1355.
    • (1998) Transplant Proc , vol.30 , pp. 1355
    • Neylan, J.F.1
  • 49
    • 75749114491 scopus 로고    scopus 로고
    • CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacroli-mus in bioequivalence study
    • Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A5*3 genotype associated with intrasubject pharmacokinetic variation toward tacroli-mus in bioequivalence study. Ther Drug Monit 2010; 32: 67.
    • (2010) Ther Drug Monit , vol.32 , pp. 67
    • Yong Chung, J.1    Jung Lee, Y.2    Bok Jang, S.3
  • 50
    • 34547687359 scopus 로고    scopus 로고
    • Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy
    • Mendonza AE, Zahir H, Gohh RY, et al. Tacrolimus in diabetic kidney transplant recipients: Pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 2007; 29: 391.
    • (2007) Ther Drug Monit , vol.29 , pp. 391
    • Mendonza, A.E.1    Zahir, H.2    Gohh, R.Y.3
  • 51
    • 11844249410 scopus 로고    scopus 로고
    • Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: An open-label, prospective, pharmacokinetic study in adult recipients
    • Kuypers DR, Vanrenterghem Y. Time to reach tacrolimus maximum blood concentration, mean residence time, and acute renal allograft rejection: An open-label, prospective, pharmacokinetic study in adult recipients. Clin Ther 2004; 26: 1834.
    • (2004) Clin Ther , vol.26 , pp. 1834
    • Kuypers, D.R.1    Vanrenterghem, Y.2
  • 52
    • 0036913473 scopus 로고    scopus 로고
    • Population pharmacokinetics of tacrolimus in adult kidney transplant recipients
    • Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660.
    • (2002) Clin Pharmacol Ther , vol.72 , pp. 660
    • Staatz, C.E.1    Willis, C.2    Taylor, P.J.3
  • 53
    • 0242351679 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation
    • Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18: 2409.
    • (2003) Nephrol Dial Transplant , vol.18 , pp. 2409
    • Anglicheau, D.1    Flamant, M.2    Schlageter, M.H.3
  • 54
    • 61349142451 scopus 로고    scopus 로고
    • Tacrolimus pharma-cokinetic drug interactions: Effectofprednisone, mycophenolic acid or sirolimus
    • Park SI, Felipe CR, Pinheiro-Machado PG, et al. Tacrolimus pharma-cokinetic drug interactions: Effectofprednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009; 23: 137.
    • (2009) Fundam Clin Pharmacol , vol.23 , pp. 137
    • Park, S.I.1    Felipe, C.R.2    Pinheiro-Machado, P.G.3
  • 55
    • 58749088941 scopus 로고    scopus 로고
    • Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring
    • Kuypers DR. Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring. Ann Transplant 2008; 13: 11.
    • (2008) Ann Transplant , vol.13 , pp. 11
    • Kuypers, D.R.1
  • 56
    • 48249120712 scopus 로고    scopus 로고
    • Corticosteroid interactions with cyclo-sporine tacrolimus mycophenolate and sirolimus: Fact or fiction?
    • Lam S, Partovi N, Ting LS, et al. Corticosteroid interactions with cyclo-sporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction? Ann Pharmacother 2008; 42: 1037.
    • (2008) Ann Pharmacother , vol.42 , pp. 1037
    • Lam, S.1    Partovi, N.2    Ting, L.S.3
  • 57
    • 0036290197 scopus 로고    scopus 로고
    • Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients
    • Jones TE, Morris RG. Pharmacokinetic interaction between tacrolimus and diltiazem: Dose-response relationship in kidney and liver transplant recipients. Clin Pharmacokinet 2002; 41: 381.
    • (2002) Clin Pharmacokinet , vol.41 , pp. 381
    • Jones, T.E.1    Morris, R.G.2
  • 58
    • 0036380025 scopus 로고    scopus 로고
    • Mechanisms of clinically relevant drug interactions associated with tacrolimus
    • Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmaco-kinet 2002; 41: 813.
    • (2002) Clin Pharmaco-kinet , vol.41 , pp. 813
    • Christians, U.1    Jacobsen, W.2    Benet, L.Z.3
  • 59
    • 0036360906 scopus 로고    scopus 로고
    • Drug interactions with tacrolimus
    • van Gelder T. Drug interactions with tacrolimus. Drug Saf 2002; 25: 707.
    • (2002) Drug Saf , vol.25 , pp. 707
    • Van Gelder, T.1
  • 60
    • 16444367741 scopus 로고    scopus 로고
    • Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients
    • Kim JS, Aviles DH, Silverstein DM, et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005; 9: 162.
    • (2005) Pediatr Transplant , vol.9 , pp. 162
    • Kim, J.S.1    Aviles, D.H.2    Silverstein, D.M.3
  • 61
    • 0041317355 scopus 로고    scopus 로고
    • Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids
    • Hesselink DA, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 2003; 56: 327.
    • (2003) Br J Clin Pharmacol , vol.56 , pp. 327
    • Hesselink, D.A.1    Ngyuen, H.2    Wabbijn, M.3
  • 62
    • 70149105801 scopus 로고    scopus 로고
    • CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole
    • Chandel N, Aggarwal PK, Minz M, et al. CYP3A5*1/*3 genotype influences the blood concentration of tacrolimus in response to metabolic inhibition by ketoconazole. Pharmacogenet Genomics 2009; 19: 458.
    • (2009) Pharmacogenet Genomics , vol.19 , pp. 458
    • Chandel, N.1    Aggarwal, P.K.2    Minz, M.3
  • 63
    • 53549126614 scopus 로고    scopus 로고
    • Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients
    • Kuypers DR, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18: 861.
    • (2008) Pharmacogenet Genomics , vol.18 , pp. 861
    • Kuypers, D.R.1    De Jonge, H.2    Naesens, M.3
  • 64
    • 77954623148 scopus 로고    scopus 로고
    • Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure
    • Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68.
    • (2010) Transplantation , vol.90 , pp. 68
    • Gaston, R.S.1    Cecka, J.M.2    Kasiske, B.L.3
  • 65
    • 67650941470 scopus 로고    scopus 로고
    • Use of cardioprotective medications in kidney transplant recipients
    • Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
    • (2009) Am J Transplant , vol.9 , pp. 1811
    • Gaston, R.S.1    Kasiske, B.L.2    Fieberg, A.M.3
  • 66
    • 75149136028 scopus 로고    scopus 로고
    • Pathological and clinical characterization of the 'troubled transplant' Data from the DeKAF study
    • Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324.
    • (2010) Am J Transplant , vol.10 , pp. 324
    • Gourishankar, S.1    Leduc, R.2    Connett, J.3
  • 67
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
    • (1976) Nephron , vol.16 , pp. 31
    • Cockcroft, D.W.1    Gault, M.H.2
  • 68
    • 52449099461 scopus 로고    scopus 로고
    • Genomic variation in myeloma: Design, content, and initial application of the bank on a cure SNP panel to detect associations with progression-free survival
    • Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design, content, and initial application of the bank on a cure SNP panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
    • (2008) BMC Med , vol.6 , pp. 26
    • Van Ness, B.1    Ramos, C.2    Haznadar, M.3
  • 69
    • 0037685262 scopus 로고    scopus 로고
    • Multiplexed genotyping with sequence-tagged molecular inversion probes
    • Hardenbol P, Baner J, Jain M, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003; 21: 673.
    • (2003) Nat Biotechnol , vol.21 , pp. 673
    • Hardenbol, P.1    Baner, J.2    Jain, M.3
  • 70
    • 70350638990 scopus 로고    scopus 로고
    • A new measure of the effective number of tests,a practical tool for comparing families of non-independent significance tests
    • Galwey NW. A new measure of the effective number of tests,a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009; 33: 559.
    • (2009) Genet Epidemiol , vol.33 , pp. 559
    • Galwey, N.W.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.